-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, UcJhFlOTlb5jp3sMqprJeO/h+zkBCpLLNx2QX9w2arK8uu5ZFYvPpCtIqUJJAB1T D5Us70ak83zxBDjYq4mLMw== 0001144204-07-057430.txt : 20071101 0001144204-07-057430.hdr.sgml : 20071101 20071031174611 ACCESSION NUMBER: 0001144204-07-057430 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20071101 DATE AS OF CHANGE: 20071031 GROUP MEMBERS: FELIX J. BAKER SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: IDERA PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000861838 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 043072298 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-50211 FILM NUMBER: 071203930 BUSINESS ADDRESS: STREET 1: 167 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 6176795500 MAIL ADDRESS: STREET 1: 167 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: HYBRIDON INC DATE OF NAME CHANGE: 19951211 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BAKER JULIAN CENTRAL INDEX KEY: 0001087939 FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: TISCH FAMILY INTERESTS STREET 2: 667 MADISON AVENUE CITY: NEW YORK STATE: NY ZIP: 10021 BUSINESS PHONE: 212-339-5600 MAIL ADDRESS: STREET 1: BAKER BROTHERS ADVISORS STREET 2: 667 MADISON AVENUE CITY: NEW YORK STATE: NY ZIP: 10021 SC 13D/A 1 v092027_sc13da.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) Idera Pharmaceuticals, Inc - -------------------------------------------------------------------------------- (Name of Issuer) Common Stock, par value $0.001 per share - -------------------------------------------------------------------------------- (Title of Class of Securities) 45168K108 ---------------------------------------------------------------------- (CUSIP Number) Leo Kirby 667 Madison Avenue, 17th Floor New York, NY 10021 (212) 521-2418 - -------------------------------------------------------------------------------- (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) October 29, 2007 ---------------------------------------------------------------------- (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box. |X| Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent. *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). Page 1 of 6 Pages SCHEDULE 13D - ------------------- ----------------- CUSIP No. 45168K108 Page 2 of 6 Pages - ------------------- ----------------- - -------------------------------------------------------------------------------- 1 NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS Julian C. Baker - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) |_| (b) |X| - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 SOURCE OF FUNDS (See Instructions) WC - -------------------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) |_| - -------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OF ORGANIZATION United States - -------------------------------------------------------------------------------- NUMBER OF 7 SOLE VOTING POWER SHARES BENEFICIALLY 0 OWNED BY -------------------------------------------------------- EACH 8 SHARED VOTING POWER REPORTING PERSON 3,828,703 WITH -------------------------------------------------------- 9 SOLE DISPOSITIVE POWER 0 -------------------------------------------------------- 10 SHARED DISPOSITIVE POWER 3,828,703 - -------------------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,828,703 - -------------------------------------------------------------------------------- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions) |_| - -------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 16.6% - -------------------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON (See Instructions) IN - -------------------------------------------------------------------------------- Page 2 of 6 Pages SCHEDULE 13D - ------------------- ----------------- CUSIP No. 45168K108 Page 3 of 6 Pages - ------------------- ----------------- - -------------------------------------------------------------------------------- 1 NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS Felix J. Baker - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) |_| (b) |X| - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 SOURCE OF FUNDS (See Instructions) WC - -------------------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) |_| - -------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OF ORGANIZATION United States - -------------------------------------------------------------------------------- NUMBER OF 7 SOLE VOTING POWER SHARES BENEFICIALLY 0 OWNED BY -------------------------------------------------------- EACH 8 SHARED VOTING POWER REPORTING PERSON 3,828,703 WITH -------------------------------------------------------- 9 SOLE DISPOSITIVE POWER 0 -------------------------------------------------------- 10 SHARED DISPOSITIVE POWER 3,828,703 - -------------------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,828,703 - -------------------------------------------------------------------------------- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions) |_| - -------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 16.6% - -------------------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON (See Instructions) IN - -------------------------------------------------------------------------------- Page 3 of 6 Pages This Amendment No. 1 to Schedule 13D is being filed by Julian C. Baker and Felix J. Baker (the "Reporting Persons") to supplement the statements on Schedule 13D previously filed by them, as heretofore amended. Except as supplemented herein, such statements, as heretofore amended and supplemented, remain in full force and effect. Item 5. Interest in Securities of the Issuer. Set forth below is the aggregate number of shares of Common Stock held, including shares that maybe acquired upon the exercise of Warrants, as of the date hereof by each of the following, together with the percentage of outstanding shares of Common Stock that such number represents based upon 23,039,949 shares outstanding as reported in the Company's Form 10Q filed on August 1, 2007. Such percentage figures are calculated on the basis that the Warrants owned by the Reporting Persons are deemed exercised for shares of Common Stock but other outstanding Warrants are not deemed converted or exercised. Percent of Class Name Number of Shares Outstanding ---------------------------------- ----------- ------- Baker Bros. Investments, L.P. 118,514 0.5% Baker Bros. Investments II, L.P. 107,105 0.5% Baker Biotech Fund I, L.P 1,177,237 5.1% Baker Brothers Life Sciences, L.P. 2,353,406 10.2% 14159, L.P. 72,441 0.3% ---------------------------------- ----------- ------- Total 3,828,703 16.6% By virtue of their ownership of entities that have the power to control the investment decisions of the limited partnerships listed in the table above, Julian C. Baker and Felix J. Baker may each be deemed to be beneficial owners of shares owned by such entities and may be deemed to have shared power to vote or direct the vote of and shared power to dispose or direct the disposition of such securities. The following transactions in Common Stock were effected by the entities noted below during the sixty days preceding the filing of this statement. None of the reporting Persons has effected any other transactions in Common Stock during this period.
- ------------------------------------------------------------------------------------------- Number of Price/ Name Date Shares Transaction Share - ------------------------------------------------------------------------------------------- Baker Brothers Investments, L.P. 10/29/2007 1,743 Sale 12.4669 - ------------------------------------------------------------------------------------------- Baker Brothers Investments II, 10/29/2007 1,574 Sale 12.4669 L.P. - ------------------------------------------------------------------------------------------- Baker Brothers Life Sciences, L.P. 10/29/2007 34,606 Sale 12.4669 - ------------------------------------------------------------------------------------------- Baker Biotech Fund I, L.P. 10/29/2007 17,311 Sale 12.4669 - ------------------------------------------------------------------------------------------- 14159, L.P. 10/29/2007 1,066 Sale 12.4669 - -------------------------------------------------------------------------------------------
Page 4 of 6 Pages
- ----------------------------------------------------------------------------------------------- Price/ Name Date Number of Shares Transaction Share - ----------------------------------------------------------------------------------------------- Baker Brothers Investments, L.P. 10/30/2007 1,628 Sale 12.0286 - ----------------------------------------------------------------------------------------------- Baker Brothers Investments II, L.P. 10/30/2007 1,471 Sale 12.0286 - ----------------------------------------------------------------------------------------------- Baker Brothers Life Sciences, L.P. 10/30/2007 32,332 Sale 12.0286 - ----------------------------------------------------------------------------------------------- Baker Biotech Fund I, L.P. 10/30/2007 16,173 Sale 12.0286 - ----------------------------------------------------------------------------------------------- 14159, L.P. 10/30/2007 996 Sale 12.0286 - ----------------------------------------------------------------------------------------------- Baker Brothers Investments, L.P. 10/31/2007 1,228 Sale 11.6995 - ----------------------------------------------------------------------------------------------- Baker Brothers Investments II, L.P. 10/31/2007 1,109 Sale 11.6995 - ----------------------------------------------------------------------------------------------- Baker Brothers Life Sciences, L.P. 10/31/2007 24,384 Sale 11.6995 - ----------------------------------------------------------------------------------------------- Baker Biotech Fund I, L.P. 10/31/2007 12,198 Sale 11.6995 - ----------------------------------------------------------------------------------------------- 14159, L.P. 10/31/2007 751 Sale 11.6995 - -----------------------------------------------------------------------------------------------
Item 7. Material to Be Filed as Exhibits. Exhibit 1. Agreement regarding the joint filing of this statement. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. October 31, 2007 By: /s/ Julian C. Baker ------------------------------ Julian C. Baker By: /s/ Felix J. Baker ------------------------------ Felix J. Baker Page 5 of 6 Pages EXHIBIT 1 AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13D relating to the Common Stock, $0.001 par value, of Idera Pharmaceuticals, Inc. is being filed with the Securities and Exchange Commission on behalf of each of them. October 31, 2007 By: /s/ Julian C. Baker ------------------------------ Julian C. Baker By: /s/ Felix J. Baker ------------------------------ Felix J. Baker Page 6 of 6 Pages -----END PRIVACY-ENHANCED MESSAGE-----